Recent Updates
Recently added Catalysts

AL-78898A

Phase 2

Exudative Age-Related Macular Degeneration | Small molecule | Ophthalmology |Alcon Inc.|Last Updated: Jun 4, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDBiomarker
Total Trials1
Total Enrollment99
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01157065Evaluation of AL-78898A in Exudative Age-Related Macular DegenerationPHASE2 COMPLETED 99Jun 1, 2011Apr 1, 2012Jun 4, 20131 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Mean Reduction From Baseline in Central Subfield (CSF) Retinal Thickness at Week 4
Week 4

The thickness of the retina was measured using a non-invasive device that produces cross-sectional and 3D images of the eye. The reduction was calculated by subtracting Week 4 visit value from the Baseline value. A positive number indicates a reduction in thickness compared to baseline, whereas a negative number indicates an increase in thickness. An increase in thickness as compared to baseline may indicate a progression of the underlying disease.

Incidence of Events of Special Interest (ESI)
Up to Day 30

An ESI was a protocol-specified event of scientific and medical concern specific to the Sponsor's product or program where ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. These adverse events could have been serious or nonserious and may have required further investigation in order to characterize and understand.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
AL-78898AEXPERIMENTALSingle 50-µL (microliter) intravitreal injection with 12 weeks follow-up
LucentisACTIVE_COMPARATORSingle 50-µL (microliter) intravitreal injection with 12 weeks follow-up
Interventions
NameTypeDescription
AL-78898ADRUGInvestigational treatment
RanibizumabDRUGAnti-vascular endothelial growth factor (VEGF) treatment
Unlock Study Design Details
Eligibility Criteria
Age Range50 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Willing to give informed consent, make the required study visits and follow instructions; * Newly diagnosed with exudative age-related macular degeneration (AMD); * Presence of primary juxta- or subfoveal choroidal neovascularization (CNV) secondary to AMD (study eye); * Best-...

Countries:United States
Unlock Eligibility Criteria